CompletedNCT04447287
A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Addiction
Medication studyAges 18–60United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Overland ParkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: June 29, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 23
- Sponsor
- Astellas Pharma Global Development, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT04447287
- Official title
Show the full official title
Phase 1b Randomized, Placebo-controlled Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Subjects With Opioid Use Disorder
Get this study by email
Recruitment & locations
CompletedOverland Park
Questions about this study
Who is behind this study?
The study sponsor is Astellas Pharma Global Development, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including ASP8062, Placebo ASP8062 and buprenorphine/naloxone.
Who was this study for?
Listed age limits: 18 years to 60 years.
